Eli Lilly (LLY) Reports No Difference Observed Between FORTEO and Risedronate in Phase III
Tweet Send to a Friend
Eli Lilly and Company (NYSE: LLY) announced data from a Phase III trial comparing the effects of FORTEO (teriparatide [rDNA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
